GeneBioTech Co. Ltd (086060) - Cash Flow Conversion Efficiency

Latest as of September 2025: 0.072x

Based on the latest financial reports, GeneBioTech Co. Ltd (086060) has a cash flow conversion efficiency ratio of 0.072x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩3.87 Billion ≈ $2.62 Million USD) by net assets (₩54.03 Billion ≈ $36.61 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.

GeneBioTech Co. Ltd - Cash Flow Conversion Efficiency Trend (2009–2024)

This chart illustrates how GeneBioTech Co. Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read GeneBioTech Co. Ltd debt and liabilities for a breakdown of total debt and financial obligations.

GeneBioTech Co. Ltd Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of GeneBioTech Co. Ltd ranked by their cash flow conversion efficiency.

Company	Cash Flow Conversion Efficiency
Novacyt PA:ALNOV	-0.067x
KD Chem Co. Ltd KQ:221980	0.024x
Marco Holdings Bhd KLSE:3514	0.057x
PLANETEL SPA F:0A7	N/A
Wulff-Yhtiot Oy HE:WUF1V	0.164x
The Peria Karamalai Tea & Produce Company Limited NSE:PKTEA	-0.004x
Manaksia Aluminium Company Limited NSE:MANAKALUCO	-0.083x
Jade Marvel Group Bhd KLSE:7043	-0.019x

Annual Cash Flow Conversion Efficiency for GeneBioTech Co. Ltd (2009–2024)

The table below shows the annual cash flow conversion efficiency of GeneBioTech Co. Ltd from 2009 to 2024. For the full company profile with market capitalisation and key ratios, see 086060 stock market capitalisation.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2024-12-31	₩50.97 Billion ≈ $34.54 Million	₩-463.87 Million ≈ $-314.36K	-0.009x	-105.97%
2023-12-31	₩48.30 Billion ≈ $32.74 Million	₩7.37 Billion ≈ $4.99 Million	0.153x	+289.60%
2022-12-31	₩45.73 Billion ≈ $30.99 Million	₩-3.68 Billion ≈ $-2.49 Million	-0.080x	-24.45%
2021-12-31	₩43.95 Billion ≈ $29.78 Million	₩-2.84 Billion ≈ $-1.93 Million	-0.065x	-216.88%
2020-12-31	₩45.04 Billion ≈ $30.52 Million	₩2.49 Billion ≈ $1.69 Million	0.055x	+196.80%
2019-12-31	₩46.93 Billion ≈ $31.80 Million	₩-2.68 Billion ≈ $-1.82 Million	-0.057x	-146.02%
2018-12-31	₩47.96 Billion ≈ $32.50 Million	₩5.96 Billion ≈ $4.04 Million	0.124x	+343.93%
2017-12-31	₩40.49 Billion ≈ $27.44 Million	₩1.13 Billion ≈ $767.40K	0.028x	-79.46%
2016-12-31	₩39.02 Billion ≈ $26.44 Million	₩5.31 Billion ≈ $3.60 Million	0.136x	+50.66%
2015-12-31	₩28.84 Billion ≈ $19.54 Million	₩2.61 Billion ≈ $1.77 Million	0.090x	-1.78%
2014-12-31	₩23.42 Billion ≈ $15.87 Million	₩2.15 Billion ≈ $1.46 Million	0.092x	-10.63%
2013-12-31	₩23.10 Billion ≈ $15.65 Million	₩2.38 Billion ≈ $1.61 Million	0.103x	-20.67%
2011-12-31	₩19.48 Billion ≈ $13.20 Million	₩2.53 Billion ≈ $1.71 Million	0.130x	+104.69%
2010-12-31	₩18.38 Billion ≈ $12.45 Million	₩1.17 Billion ≈ $789.56K	0.063x	-57.24%
2009-12-31	₩18.08 Billion ≈ $12.25 Million	₩2.68 Billion ≈ $1.82 Million	0.148x	--

About GeneBioTech Co. Ltd

KQ:086060 Korea Pharmaceuticals

Market Cap

$26.46 Million

₩39.05 Billion KRW

Market Cap Rank

#24137 Global

#1752 in Korea

Share Price

₩4665.00

Change (1 day)

+0.00%

52-Week Range

₩3435.00 - ₩5550.00

All Time High

₩10031.60